Shire Plc reported revenue of $4.3 billion in 2011, up by 23%, reflecting strong demand for the attention deficit hyperactivity disorder (ADHD) treatments, Vyvanse and Intuniv. Sales were also helped by a regenerative medicines acquisition. ---Subscribe to MedNous to access this article--- Company News
